ATE452900T1 - Impfstoff gegen das west-nile-virus - Google Patents

Impfstoff gegen das west-nile-virus

Info

Publication number
ATE452900T1
ATE452900T1 AT03783570T AT03783570T ATE452900T1 AT E452900 T1 ATE452900 T1 AT E452900T1 AT 03783570 T AT03783570 T AT 03783570T AT 03783570 T AT03783570 T AT 03783570T AT E452900 T1 ATE452900 T1 AT E452900T1
Authority
AT
Austria
Prior art keywords
west nile
nile virus
vaccine against
vaccines
methods
Prior art date
Application number
AT03783570T
Other languages
English (en)
Inventor
Juan Arroyo
John Catalan
Charles Miller
Thomas Monath
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Application granted granted Critical
Publication of ATE452900T1 publication Critical patent/ATE452900T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03783570T 2002-11-15 2003-11-13 Impfstoff gegen das west-nile-virus ATE452900T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42659202P 2002-11-15 2002-11-15
PCT/US2003/036623 WO2004045529A2 (en) 2002-11-15 2003-11-13 West nile virus vaccine

Publications (1)

Publication Number Publication Date
ATE452900T1 true ATE452900T1 (de) 2010-01-15

Family

ID=32326380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03783570T ATE452900T1 (de) 2002-11-15 2003-11-13 Impfstoff gegen das west-nile-virus

Country Status (15)

Country Link
US (2) US7507415B2 (de)
EP (1) EP1575979B1 (de)
JP (1) JP4683926B2 (de)
KR (1) KR101150584B1 (de)
AT (1) ATE452900T1 (de)
AU (1) AU2003290985B2 (de)
BR (1) BRPI0316346B1 (de)
CA (1) CA2505942C (de)
DE (1) DE60330708D1 (de)
ES (1) ES2337893T3 (de)
IL (2) IL168584A (de)
MX (1) MXPA05005140A (de)
RU (1) RU2376374C2 (de)
WO (1) WO2004045529A2 (de)
ZA (1) ZA200503871B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
CN1551782A (zh) * 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
WO2004045529A2 (en) 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
CN101090966B (zh) 2004-12-24 2012-07-04 财团法人阪大微生物病研究会 具有减毒日本脑炎病毒基因作为主链的减毒嵌合黄病毒
CA2605924A1 (en) * 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
CA2616026A1 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
MX2009004862A (es) 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
AU2007353773A1 (en) * 2006-12-22 2008-11-27 Dow Agrosciences Llc Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (de) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilisierungssubstanz und Impfzusammensetzung, die ein oder mehrere abgeschwächte lebende Flaviviridae enthält
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
EP2473624B1 (de) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Test für dengue-virus
EP2550292B1 (de) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus-wirtsbereichsmutationen und verwendungen davon
WO2012003320A2 (en) 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
WO2013138670A1 (en) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Yellow fever virus ns5 mutants as flavivirus vaccine candidates
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
EP1018556B1 (de) 1991-09-19 2005-11-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimäre und/oder wachstumsgehemmte Flaviviren
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
EP0977587B1 (de) * 1997-02-28 2005-06-15 Acambis Inc. Chimäre impfstoffe gegen flaviviren
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
CN1551782A (zh) * 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
KR101131579B1 (ko) 2001-10-19 2012-03-30 사노피 파스테르 바이오로직스 씨오 동물의 플라비바이러스 감염 예방 및 치료 방법
DE20120256U1 (de) * 2001-12-14 2002-03-07 Häfele GmbH & Co., 72202 Nagold Beschlag
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2004045529A2 (en) 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Also Published As

Publication number Publication date
EP1575979A4 (de) 2006-06-21
KR20050072143A (ko) 2005-07-08
WO2004045529A2 (en) 2004-06-03
US8088391B2 (en) 2012-01-03
BR0316346A (pt) 2005-09-27
JP2006506092A (ja) 2006-02-23
MXPA05005140A (es) 2005-08-19
DE60330708D1 (de) 2010-02-04
ZA200503871B (en) 2006-08-30
HK1083192A1 (en) 2006-06-30
EP1575979B1 (de) 2009-12-23
WO2004045529A3 (en) 2004-08-26
RU2005118419A (ru) 2006-01-20
AU2003290985B2 (en) 2010-04-01
ES2337893T3 (es) 2010-04-30
US7507415B2 (en) 2009-03-24
IL168584A (en) 2010-12-30
US20050053624A1 (en) 2005-03-10
IL202978A0 (en) 2011-08-01
AU2003290985A1 (en) 2004-06-15
EP1575979A2 (de) 2005-09-21
KR101150584B1 (ko) 2012-06-27
IL202978A (en) 2013-11-28
CA2505942A1 (en) 2004-06-03
RU2376374C2 (ru) 2009-12-20
US20070275015A9 (en) 2007-11-29
JP4683926B2 (ja) 2011-05-18
CA2505942C (en) 2012-03-13
US20100086564A1 (en) 2010-04-08
BRPI0316346B1 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
WO2003101397A3 (en) Tetravalent dengue vaccines
NO20070988L (no) Vaksine for forebygging og behandling av HIV-infeksjon
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE426412T1 (de) Adjuvante influenza-vakzine
NO20061911L (no) Immunogene sammensetninger
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
MY148075A (en) Vaccines against japanese encephalitis virus and west nile virus
EP1545599A4 (de) Immunogene zusammensetzungen und ihre diagnostische und therapeutische verwendung
EP1307130A4 (de) Impfstoff gegen menschlichen immunschwächevirus
CY2016018I1 (el) Εμβολιο κατα του ιου του δυτικου νειλου
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
DK1520587T3 (da) Allergivaccinesammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf til allergibehandling
MY192543A (en) Dengue virus vaccine compositions and methods of use thereof
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE380557T1 (de) E. coli vakzin zur protektion von geflügel gegen colibazillose
BRPI0516314A (pt) uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
AU2003253894A8 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
ATE467424T1 (de) Escape-mutanten des newcastle-disease-virus als marker-vakzine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties